Invivoscribe Technologies Inc, San Diego, a privately-held life science company, introduces Genection Inc.
Genection provides physicians with a dedicated online platform for global access to the entire clinically-actionable [removed]genetic test menu[/removed], including routine and esoteric genetic tests, exome and [removed]whole genome sequencing[/removed], cancer somatic mutation testing, and [removed]pharmacogenomics[/removed].
Genection’s model is not payor-driven, so prescribing physicians have access to genetic tests that may presently be unavailable, overlooked, or even inaccessible through their patients’ managed care plans and health care institutions.
The company offers online ordering, seamless linking of multiple CLIA- and CAP-accredited laboratories for reporting and interpretation, and integrated service offerings such as next generation sequencing and advanced bioinformatics in a singular location.
“Clinicians spend too much of their time identifying and ordering clinically relevant genetic tests, while struggling to keep abreast of the flood of clinical information around new biomarkers,” says Bradley Patay, MD, Genection’s chief medical officer. “In addition to the broad selection of genetic tests available to order through their service, Genection offers one of the most relevant new genomic testing services next generation sequencing used to detect driver mutations in cancer.”
Oncologists appreciate that current, more-effective and individualized cancer treatment programs require improved diagnostic stratification of their patients, the company says, adding that using targeted gene assays for deep sequencing of oncogenes and tumor-suppressor genes, and exome sequencing to identify rare or unknown genes that may contribute to an individual’s cancer, an oncologist can better identify the underlying cause of a patient’s tumor to create a more targeted treatment plan.
Genection has agreements in place with several top CLIA- and CAP-accredited laboratories as well as sequencing centers. “Our initial partners include ARUP Laboratories, Foundation Medicine, Cypher Genomics, the Laboratory for Personalized Molecular Medicine (LabPMM) in the United States, as well as its ISO15189-compliant laboratory (LabPMM GmbH) in Martinsried, Germany,” says Suzanne Graham, senior manager of business development. “Genection also has established relationships with sequencing providers, including Illumina and Ambry Genetics.” The company also has alliances with a consortium of genetic counselors, to provide current, informed decision-making support, reducing costs of the informed consent process, and helping to avoid unnecessary testing.
“In order to make personalized molecular medicine a clinical reality, new platforms need to be developed for the delivery of health care,” Patay says, adding that the company seeks to accelerate this adoption process. “The combination of CLIA-validated genetic testing, whole-exome or whole-genome sequencing and broad targeted assays, along with critical bioinformatics, analytic tools, and interpretative guidelines will contribute to timely definitive diagnoses for patients with rare, unexplained diseases or complex diseases; in essence, this integration will speed delivery of genomic test results and improve patient care.”
The company’s Web application provides HIPAA-compliant, secure patient data management for physicians and health organizations. As patient care moves to more team-based management, it is vital for patient information to integrate with several clinicians, and not be limited to one single provider, according to the company. The company allows clinicians to share test results and genetic information with other health care providers, which can assist in a diagnosis for a patient and accelerate creation of individualized treatment plans and potentially life-saving therapies.
Genection also serves as the gateway for the global [removed]Together We Cure[/removed] initiative, which allows acute myeloid leukemia (AML) patients and physicians to share clinical information to facilitate more rapid development of AML targeted therapeutics.
Invivoscribe Technologies was founded 18 years ago by Jeffrey E. Miller, PhD, chairman and CEO, who will serve as president of Genection.